Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

September 9, 2026

To
Corporate Relationship Department
BSE Ltd
Mumbai – 400 001

Scrip Code: **524816**

To
The Manager – Listing
National Stock Exchange of India Ltd
Mumbai – 400 051

Scrip Code: **NATCOPHARM**

Dear Sirs/Madam(s),

Sub: Outcome of Board Meeting pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

In furtherance to the intimation dated August 14, 2026 and pursuant to Regulation 30 read with Schedule III and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations"), please be informed that the Board of Directors at their meeting held on Wednesday, September 9, 2026, has inter-alia considered and approved the following:

1. Issuance of fully paid up equity shares of the Company of face value of ₹2 each ("Rights Equity Shares") for an amount not exceeding ₹1,300 crore (Rupees One Thousand and Three Hundred Crore only) by way of a rights issue to the eligible equity shareholders of the Company, as on the record date (to be determined and notified subsequently), in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations"), subject to such regulatory and statutory approvals, as may be required under the applicable laws.

2. Constitution of the Fund-Raising Committee of the Board with the following members and delegation of such powers as may be necessary to give effect to the Rights Issue:

    i. Sri V.C. Nannapaneni, Chairman
    ii. Sri Rajeev Nannapaneni, Member
    iii. Sri P.S.R.K. Prasad, Member

3. The Draft Letter of Offer for the Rights Issue, in accordance with the provisions of the Companies Act, 2013, the SEBI (ICDR) Regulations and other applicable laws.

4. Update on the Scheme of Arrangement (Demerger):

    This is in continuation of our earlier intimation about the scheme of arrangement (Demerger) between Natco Pharma Limited ("Demerged Company" or "Company") and Natco Crop Health Sciences Limited ("Resulting Company") and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Scheme" or "Scheme of Arrangement").

The Scheme was submitted to the Stock Exchanges in accordance with the applicable provisions of Regulation 37 of the SEBI LODR Regulations read with the SEBI Scheme Circular and the Company has received the Observation Letter from both the stock exchanges.

The Company has not filed the Scheme and related applications with the Hon'ble National Company Law Tribunal.

The fund raising by way of a Rights Issue proposed at the meeting of the board of directors held on September 09, 2026 is expected to result in change to the Company's capital structure and shareholding pattern and consequently would require necessary changes to the Scheme.

Accordingly, the Board at its meeting held on September 09, 2026, has considered and decided to consequentially make necessary changes to the Scheme appropriately post completion of the Rights Issue with a view to, inter alia, maintain the share swap ratio in the revised Scheme the same as the one proposed in the Scheme in respect of which the Company has received the Observation Letters from the Stock Exchanges. The Company proposes to make appropriate filings of such revised Scheme with the Stock Exchanges post completion of the now proposed Rights Issue as aforesaid.

The disclosure relating to the rights issue, as required pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached as per **Annexure I**.

Meeting commenced at 10.35 a.m. and concluded at 11:35 a.m.

We request you to take the aforesaid on record.

Thanking you,

Yours faithfully,

For Natco Pharma Limited

VENKAT RAMESH CHEKURI

Digitally signed by VENKAT RAMESH CHEKURI
Date: 2026.09.09 11:42:34 +05'30'

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl.: as above

Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Annexure I

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Details
1	Type of securities proposed to be issued (viz. equity shares, convertibles, etc.)	Equity shares of the Company of face value of ₹2 each
2	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Rights issue to the eligible equity shareholders of the Company, as on the record date. The total number of Rights Equity Shares to be issued will be determined upon finalisation of the issue price and the rights entitlement ratio.
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Not exceeding ₹ 1,300 crore
4	In case of preferential issue the listed entity shall disclose the following additional details to the stock exchange(s)	Not Applicable
5	In case of bonus issue the listed entity shall disclose the following additional details to the stock exchange(s)	Not Applicable
6	In case of issuance of depository receipts (ADR/GDR) or FCCB the listed entity shall disclose following additional details to the stock exchange(s)	Not Applicable
7	In case of issuance of debt securities or other non-convertible securities the listed entity shall disclose following additional details to the stock exchange(s):	Not Applicable
8	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not Applicable